Fennec Pharmaceuticals Inc.: dividend

FENCNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$11.62

November 13, 2026Market cap $401M

What Ploutos Investor adds for Fennec Pharmaceuticals

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 14 fiscal years, from 2011
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The filings show substantial debt that is not stated in a form we can read. The debt, net cash, enterprise value, the multiples built on it and the return on invested capital would leave that debt out, so we leave them out.
  • Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.

Fennec Pharmaceuticals pays no dividend

It paid no dividend in any of the fiscal years we hold, nor over the last 12 months. Nor does it buy back shares: its share count rose 24.9% in a year.

All dividend stocks

The full analysis

What do Fennec Pharmaceuticals's filings show?

The dividend is one part of Fennec Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about FENC's dividend

Didn't find what you were looking for?

Ask us
Does FENC pay a dividend?

It paid no dividend in any of the fiscal years we hold, nor over the last 12 months. Nor does it buy back shares: its share count rose 24.9% in a year.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.